When was Alveron Pharma founded?

Alveron Pharma was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Alveron Pharma located?

Alveron Pharma is headquartered in Nijmegen, Netherlands.

How many employees does Alveron Pharma have?

As of Aug 31, 2026, the latest employee count at Alveron Pharma is 5.

Is Alveron Pharma a funded company?

Alveron Pharma is a funded company, having raised a total of $11.8M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 16, 2019.

When was the latest funding round of Alveron Pharma?

Alveron Pharma's latest funding was a $***** Series A round on Oct 07, 2021, with participation from 3 investors. Its primary sector is Hematology. In Netherlands, the Hematology sector has seen $70M in funding in 2026 to date.

Where does Alveron Pharma rank among its competitors?

Alveron Pharma ranks 17th amongst 47 active competitors, of which 22 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Remedium Bio, which secured $10M in Aug, 2026.

Who are the top competitors of Alveron Pharma?

Alveron Pharma's top competitors include Varmx, TargED and Remedium Bio. Among them, Remedium Bio secured the most recent funding round in August, 2026.

Alveron Pharma - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drugs to treat haemorrhagic stroke or intracranial haemorrhage. The company is focused on developing a drug called OKL-1111, which is being positioned as a rapid, first-line therapy for intracranial hemorrhage (ICH).

Website: www.alveron.com/
Email ID: *****@alveron.com

Key Metrics

Founded Year

2019

Location

Nijmegen, Netherlands

Stage

Series A

Total Funding

$11.8M in 3 rounds

Latest Funding Round

Series A, Oct 07, 2021, $*****

Investors

Thuja Capital & 3 more

Ranked

17^th among 47 active competitors

Employee Count

5 as on Aug 31, 2026

Similar Companies

Varmx & 57 more

View Alveron Pharma's full profile

Alveron Pharma has raised a total funding of $11.8M over 3 rounds. Its first funding round was on May 16, 2019. Its latest funding round was a Series A round on Oct 07, 2021 for $*****. 3 investors participated in its latest round. Alveron Pharma has 4 institutional investors.

Here is the list of recent funding rounds of Alveron Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 07, 2021	1515125	Series A	2858068	7141450	9595278	5156042
Oct 07, 2021	4355947	Conventional Debt	4711014	9460352	5461142	Rijksdienst voor Ondernemend Nederland
May 16, 2019	6068818	Series A	3225360	8919125	Thuja Capital & 2 more	3002668

Access funding benchmarks and valuations. Sign up today!

View details of Alveron Pharma's funding rounds and investors

Alveron Pharma's employee count trend

Alveron Pharma has 5 employees as of Aug 26. Here is Alveron Pharma's employee count trend over the years:

Uncover Alveron Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alveron Pharma include Varmx, TargED and Remedium Bio. Here is the list of Top 10 competitors of Alveron Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Varmx 2015, Leiden (Netherlands), Series B	Therapeutic proteins to restore blood clotting in bleeding patients	$77.2M	BioGeneration Ventures, InnovationQuarter ... & 13 others	58/100
2nd	TargED 2020, Utrecht (Netherlands), Series A	Developer of biological drugs for the treatment of thrombosis	$82.8M	Sunstone, Hadean Ventures & 8 others	56/100
3rd	Remedium Bio 2020, Needham (United States), Series A	Developer of gene therapies for a broad range of diseases	$15M	LifeSpan Vision Ventures, hkxcapital.com ... & 10 others	56/100
4th	Bioxodes 2013, Marche en Famenne (Belgium), Series A	Developer of novel peptide therapies for prevention of thrombosis	$45.4M	SFPI, Newton Biocapital & 3 others	55/100
5th	Anthos Therapeutics 2019, Cambridge (United States), Acquired	Developer of novel anticoagulants for thrombosis treatment	$250M	Novartis, Blackstone & 3 others	51/100
6th	NuvOx Therapeutics 2008, Tucson (United States), Funding Raised	Developer of an oxygen therapeutic drug designed to reverse tissue hypoxia	-	Pasadena Angels, Military Health & 1 others	49/100
7th	S&E bio 2019, Seoul (South Korea), Series A	Developer of cell therapies for neurological disorders	$7.34M	LSK investment, Company K Partners & 2 others	49/100
8th	Ever Supreme Bio Technology 2016, Taichung (Taiwan), Public	Developer of immune cell and stem cell therapies for multiple diseases	-	-	45/100
9th	Freeox Biotech 2017, Barcelona (Spain), Seed	Developer of therapies for treating ischaemic stroke	$573K	Catalonia Trade & Investment, EIT Health & 2 others	45/100
10th	Acticor Biotech 2013, Paris (France), Public	Developing immunotherapeutics for treating ischemic stroke	$31.4M	Newton Biocapital, GO CAPITAL & 7 others	45/100
17th	Alveron Pharma 2019, Nijmegen (Netherlands), Series A	Developer of drugs to treat haemorrhagic stroke or intracranial haemorrhage	$11.8M	Thuja Capital, Waterman Ventures & 2 others	38/100